» Articles » PMID: 36920176

A Novel Risk Score Model Based on Pyroptosis-related Genes for Predicting Survival and Immunogenic Landscape in Hepatocellular Carcinoma

Overview
Specialty Geriatrics
Date 2023 Mar 15
PMID 36920176
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer worldwide, with high incidence and mortality. Pyroptosis, a form of inflammatory-regulated cell death, is closely associated with oncogenesis.

Methods: Expression profiles of HCC were downloaded from the TCGA database and validated using the ICGC and GEO databases. Consensus clustering analysis was used to determine distinct clusters. The pyroptosis-related genes (PRGs) included in the pyroptosis-related signature were selected by univariate Cox regression and LASSO regression analysis. Kaplan-Meier and receiver operating characteristic (ROC) analyses were performed to estimate the prognostic potential of the model. The characteristics of infiltration of immune cells between different groups of HCC were explored.

Results: Two independent clusters were identified according to PRG expression. Cluster 2 showed upregulated expression, poor prognosis, increased immune cell infiltration and worse immunotherapy response than cluster 1. A prognostic risk signature consisting of five genes (GSDME, NOD1, PLCG1, NLRP6 and NLRC4) was identified. In the high-risk score group, HCC patients showed decreased survival rates. In particular, multiple clinicopathological characteristics and immune cell infiltration were significantly associated with the risk score. Notably, the 5 PRGs in the risk score have been implicated in carcinogenesis, immunological pathways and drug sensitivity.

Conclusions: A prognostic signature comprising five PRGs can be used as a potential prognostic factor for HCC. The PRG-related signature provides an in-depth understanding of the association between pyroptosis and chemotherapy or immunotherapy for HCC patients.

Citing Articles

Gasdermin E mediates pyroptosis in the progression of hepatocellular carcinoma: a double-edged sword.

Lu Y, Xu J, Lin H, Zhu M, Li M Gastroenterol Rep (Oxf). 2024; 12:goae102.

PMID: 39526199 PMC: 11549059. DOI: 10.1093/gastro/goae102.


Pyroptosis and chemical classification of pyroptotic agents.

Hara M, Ramadan M, Abdelhameid M, Taher E, Mohamed K Mol Divers. 2024; .

PMID: 39316325 DOI: 10.1007/s11030-024-10987-6.


Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review).

Liu R, Yu X, Yan S, Guo Z, Zao X, Zhang Y Int J Oncol. 2024; 64(6).

PMID: 38757345 PMC: 11095606. DOI: 10.3892/ijo.2024.5651.


Exploration of prognostic and treatment markers in hepatocellular carcinoma via GPCR-related genes analysis.

Wang Y, Jin B, Wu X, Xing J, Zhang B, Chen X Heliyon. 2024; 10(9):e29659.

PMID: 38694033 PMC: 11058304. DOI: 10.1016/j.heliyon.2024.e29659.


Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.

Zhu J, Huang Q, Peng X, Luo C, Liu Z, Liu D Front Immunol. 2023; 14:1218661.

PMID: 37662906 PMC: 10471990. DOI: 10.3389/fimmu.2023.1218661.

References
1.
Macek Jilkova Z, Aspord C, Decaens T . Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers (Basel). 2019; 11(10). PMC: 6826488. DOI: 10.3390/cancers11101554. View

2.
Zhu X, Li K, Sun H . Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis. 2020; 7(3):359-369. PMC: 7452398. DOI: 10.1016/j.gendis.2020.02.002. View

3.
Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. View

4.
Fernandez-Garcia V, Gonzalez-Ramos S, Martin-Sanz P, Laparra J, Bosca L . NOD1-Targeted Immunonutrition Approaches: On the Way from Disease to Health. Biomedicines. 2021; 9(5). PMC: 8148154. DOI: 10.3390/biomedicines9050519. View

5.
Yao L, Li J, Xu Z, Yan Y, Hu K . GSDMs are potential therapeutic targets and prognostic biomarkers in clear cell renal cell carcinoma. Aging (Albany NY). 2022; 14(6):2758-2774. PMC: 9004560. DOI: 10.18632/aging.203973. View